Treace Medical Shares Interim Data From Corrective Toe Surgery Trial

·1 分鐘文章
  • Treace Medical Concepts Inc (NASDAQ: TMCI) announced an audio poster presentation of the latest interim analysis from the ALIGN3D clinical study following the Lapiplasty Procedure for surgical treatment of hallux valgus (bunions).

  • The data showed:

    • Early return to weight bearing in a walking boot at an average of 8.3 days.

    • A low recurrence rate, defined as loss of radiographic correction, was observed in 1.4% of patients (2 out of 144).

    • An 81% reduction in pain (Visual Analog Scale) was reported at 24 months post-procedure (n=107).

  • The interim analysis also continued to report statistically significant improvement in Patient-Reported Outcomes.

  • At 24 months post-surgery (n=107), an 82% and 84% improvement was observed in walking/standing and social interaction, respectively.

  • Further, statistically significant improvements in physical, mental, and social health scores were reported.

  • Price Action: TMCI shares closed 4.37% lower at $23.33 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga does not provide investment advice. All rights reserved.